Tianjin TEDA Biomedical Engineering Company Limited (TEDA Biomedical) submitted its Monthly Return to Hong Kong Exchanges and Clearing on 03 June 2026, confirming a stable share-capital structure for the period ended 31 May 2026.

Authorised and Registered Capital • H-share authorisation stood at 1,436.40 million shares with a par value of RMB 0.10 each, equivalent to RMB 143.64 million. • Domestic share authorisation remained at 697.50 million shares, par value RMB 0.10 each, or RMB 69.75 million. • Combined authorised share capital therefore totalled RMB 213.39 million, unchanged from the previous month.

Issued Shares and Public Float • Issued H shares totalled 1,436.40 million, while issued domestic shares were 697.50 million. • No treasury shares were recorded, and there were no increases or decreases in either class during the month. • The company confirmed compliance with the minimum 25% public-float requirement for its H shares.

Corporate Actions • No share options, warrants, convertible instruments or other equity-linked agreements were outstanding or exercised during May. • The company reported no Hong Kong Depositary Receipts and no other share repurchases, cancellations or redemptions.

The filing indicates that TEDA Biomedical’s capital base and share distribution remained steady throughout May 2026, with full adherence to Hong Kong listing requirements.